Disease · MONDO_0019082
Targets28
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 28
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IGHE | Immunoglobulin heavy constant epsilon | 2 | Ig epsilon chain C region inhibitor | Phase 3 | https://conductscience.org/library/genes/3497 | Drugs and targets |
| IL12B | Interleukin-12 | 2 | Interleukin-12 inhibitor; Interleukin-23 inhibitor | Phase 2 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL23A | Interleukin-23 | 2 | Interleukin-23 inhibitor | Phase 2 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| C1S | Complement C1s subcomponent | 1 | Complement C1s inhibitor | Phase 1 | https://conductscience.org/library/genes/716 | Drugs and targets |
| C5 | Complement C5 | 1 | Complement C5 inhibitor | Phase 3 | https://conductscience.org/library/genes/727 | Drugs and targets |
| C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 1 | C5a anaphylatoxin chemotactic receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/728 | Drugs and targets |
| CCL11 | Eotaxin | 1 | Eotaxin inhibitor | Phase 2 | https://conductscience.org/library/genes/6356 | Drugs and targets |
| CXCR1 | C-X-C chemokine receptor type 1 | 1 | Interleukin-8 receptor A modulator | Phase 2 | https://conductscience.org/library/genes/3577 | Drugs and targets |
| CXCR2 | C-X-C chemokine receptor type 2 | 1 | Interleukin-8 receptor B modulator | Phase 2 | https://conductscience.org/library/genes/3579 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| DHODH | Dihydroorotate dehydrogenase (quinone), mitochondrial | 1 | Dihydroorotate dehydrogenase inhibitor | Phase 2 | https://conductscience.org/library/genes/1723 | Drugs and targets |
| FCGRT | IgG receptor FcRn large subunit p51 | 1 | IgG receptor FcRn large subunit p51 antagonist | Phase 3 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| IL12A | Interleukin-12 | 1 | Interleukin-12 inhibitor | Phase 2 | https://conductscience.org/library/genes/3592 | Drugs and targets |
| IL17A | Interleukin-17A | 1 | Interleukin 17A inhibitor | Phase 2 | https://conductscience.org/library/genes/3605 | Drugs and targets |
| IL4R | Interleukin-4 receptor subunit alpha | 1 | Interleukin-4 receptor subunit alpha antagonist | Approval | https://conductscience.org/library/genes/3566 | Drugs and targets |
| IL5 | Interleukin-5 | 1 | Interleukin-5 inhibitor | Phase 2 | https://conductscience.org/library/genes/3567 | Drugs and targets |
| IL5RA | Interleukin-5 receptor subunit alpha | 1 | Interleukin-5 receptor subunit alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/3568 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 2 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 2 | https://conductscience.org/library/genes/3615 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019082/targets